肺炎患者的辅助皮质类固醇治疗：精准医学方法。
Adjunct corticosteroid treatment in patients with pneumonia: A precision medicine approach.
机构信息
Intensive Care Unit, Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
出版信息
Bosn J Basic Med Sci. 2019 Nov 8;19(4):315-320. doi: 10.17305/bjbms.2019.3977.
Abstract
Pneumonia is the leading infectious cause of death worldwide. While inflammation is critically important in host response to microbial invasion, exaggerated inflammation can damage the lungs, contributing to respiratory failure and mortality. Corticosteroids are effective in reducing inflammation and can also cause immune suppression. Presently, clinicians are unable to reliably distinguish between exaggerated and appropriate immune response and thus cannot rapidly identify patients most likely to benefit from adjunctive corticosteroids. In this review, we propose a biomarker-guided, precision medicine approach to corticosteroid treatment, aimed to give these medications at appropriate dose and time and only to patients who have exaggerated inflammation.
摘要
肺炎是全球范围内导致死亡的主要感染性病因。尽管炎症在宿主抵御微生物入侵的过程中起着至关重要的作用，但过度的炎症反应可损伤肺部，导致呼吸衰竭和死亡。皮质类固醇在减轻炎症反应方面具有确切疗效，但同时也可导致免疫抑制。目前，临床医生无法可靠地区分过度和适当的免疫反应，因此无法迅速识别最有可能从皮质类固醇辅助治疗中获益的患者。在本综述中，我们提出了一种基于生物标志物的精准医学方法来指导皮质类固醇治疗，旨在给予合适剂量和时间的皮质类固醇药物，并仅用于存在过度炎症的患者。
相似文献
1
Adjunct corticosteroid treatment in patients with pneumonia: A precision medicine approach.肺炎患者的辅助皮质类固醇治疗：精准医学方法。
Bosn J Basic Med Sci. 2019 Nov 8;19(4):315-320. doi: 10.17305/bjbms.2019.3977.
2
Do corticosteroids improve outcome for any critical illness?皮质类固醇是否能改善任何危重病的预后？
Curr Opin Anaesthesiol. 2013 Apr;26(2):164-70. doi: 10.1097/ACO.0b013e32835e820e.
3
Precision medicine for the treatment of severe pneumonia in intensive care.重症监护中治疗重症肺炎的精准医学
Expert Rev Respir Med. 2016;10(3):297-316. doi: 10.1586/17476348.2016.1144477. Epub 2016 Feb 9.
4
Corticosteroid treatment in severe community-acquired pneumonia: duration of treatment affects control of systemic inflammation and clinical improvement.重症社区获得性肺炎的皮质类固醇治疗：治疗持续时间影响全身炎症的控制和临床改善。
Intensive Care Med. 2011 Sep;37(9):1553-4. doi: 10.1007/s00134-011-2274-5. Epub 2011 Jun 18.
5
Outcomes of corticosteroid treatment in critical Ill adult patients with respiratory viruses-related community acquired pneumonia - a propensity-matched case control study.重症成人呼吸病毒相关社区获得性肺炎患者皮质类固醇治疗结局的一项倾向评分匹配病例对照研究。
J Microbiol Immunol Infect. 2023 Aug;56(4):757-765. doi: 10.1016/j.jmii.2023.02.009. Epub 2023 Mar 16.
6
Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.危重症患者危重症相关皮质类固醇功能不全（CIRCI）诊断与管理指南（第一部分）：危重症医学会（SCCM）和欧洲重症监护医学学会（ESICM），2017年
Crit Care Med. 2017 Dec;45(12):2078-2088. doi: 10.1097/CCM.0000000000002737.
7
Cortisol levels and corticosteroid administration fail to predict mortality in critical illness: the confounding effects of organ dysfunction and sex.皮质醇水平和皮质类固醇给药无法预测危重症患者的死亡率：器官功能障碍和性别的混杂效应
Arch Surg. 2005 Jul;140(7):661-8; discussion 669. doi: 10.1001/archsurg.140.7.661.
8
Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study.指导 COVID-19 危重症患者个体化类固醇治疗的主要候选变量：CIBERESUCICOVID 研究。
Intensive Care Med. 2022 Jul;48(7):850-864. doi: 10.1007/s00134-022-06726-w. Epub 2022 Jun 21.
9
Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine.危重症成年患者皮质类固醇功能不全的诊断与管理建议：美国危重病医学会国际特别工作组的共识声明
Crit Care Med. 2008 Jun;36(6):1937-49. doi: 10.1097/CCM.0b013e31817603ba.
10
Personalized treatment of severe pneumonia in cancer patients.个体化治疗癌症患者的重症肺炎。
Expert Rev Anti Infect Ther. 2015;13(11):1319-24. doi: 10.1586/14787210.2015.1085304. Epub 2015 Sep 7.
引用本文的文献
1
Efficacy of doxycycline therapy for macrolide-resistant Mycoplasma pneumoniae pneumonia in children at different periods.多西环素治疗不同时期儿童大环内酯类耐药肺炎支原体肺炎的疗效。
Ital J Pediatr. 2024 Mar 5;50(1):38. doi: 10.1186/s13052-024-01615-y.
2
Precision medicine for corticotherapy in COVID-19.新冠肺炎皮质激素治疗的精准医学
Intensive Care Med. 2022 Jul;48(7):926-929. doi: 10.1007/s00134-022-06751-9. Epub 2022 Jun 22.
3
Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature.社区获得性肺炎中的皮质类固醇：当前文献综述
J Pharm Technol. 2021 Jun;37(3):152-160. doi: 10.1177/8755122521995587. Epub 2021 Feb 22.
4
Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report.在一名感染新型冠状病毒肺炎的年轻肾移植受者中停用吗替麦考酚酯：一例病例报告。
Medicine (Baltimore). 2020 Jun 12;99(24):e20481. doi: 10.1097/MD.0000000000020481.
本文引用的文献
1
Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.危重症患者危重症相关皮质类固醇激素缺乏症（CIRCI）诊断与管理指南（第二部分）：危重症医学会（SCCM）和欧洲重症监护医学学会（ESICM），2017年
Crit Care Med. 2018 Jan;46(1):146-148. doi: 10.1097/CCM.0000000000002840.
2
Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.危重症患者危重症相关皮质类固醇功能不全（CIRCI）诊断与管理指南（第一部分）：危重症医学会（SCCM）和欧洲重症监护医学学会（ESICM），2017年
Crit Care Med. 2017 Dec;45(12):2078-2088. doi: 10.1097/CCM.0000000000002737.
3
Efficacy of corticosteroid treatment for severe community-acquired pneumonia: A meta-analysis.糖皮质激素治疗重症社区获得性肺炎的疗效：Meta 分析。
Am J Emerg Med. 2018 Feb;36(2):179-184. doi: 10.1016/j.ajem.2017.07.050. Epub 2017 Jul 15.
4
Prevention of ventilator-associated pneumonia: Use of the care bundle approach.呼吸机相关性肺炎的预防：采用集束化护理方法。
Am J Infect Control. 2016 Oct 1;44(10):e173-e176. doi: 10.1016/j.ajic.2016.04.237. Epub 2016 Jul 4.
5
Adjunctive Corticotherapy for Community Acquired Pneumonia: A Systematic Review and Meta-Analysis.辅助性皮质激素疗法治疗社区获得性肺炎：一项系统评价与Meta分析
PLoS One. 2015 Dec 7;10(12):e0144032. doi: 10.1371/journal.pone.0144032. eCollection 2015.
6
Efficacy and Safety of Corticosteroids for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis.糖皮质激素治疗社区获得性肺炎的疗效和安全性：系统评价和荟萃分析。
Chest. 2016 Jan;149(1):209-19. doi: 10.1378/chest.15-1733. Epub 2016 Jan 6.
7
What's new in severe community-acquired pneumonia? Corticosteroids as adjunctive treatment to antibiotics.重症社区获得性肺炎有哪些新进展？皮质类固醇作为抗生素的辅助治疗。
Intensive Care Med. 2016 Aug;42(8):1276-8. doi: 10.1007/s00134-015-4042-4. Epub 2015 Sep 14.
8
Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.类风湿关节炎患者的带状疱疹再激活：疾病特征及改善病情抗风湿药分析
Arthritis Care Res (Hoboken). 2015 Dec;67(12):1671-8. doi: 10.1002/acr.22628.
9
Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.糖皮质激素对高炎症反应的住院重症社区获得性肺炎患者治疗失败的影响：一项随机临床试验。
JAMA. 2015 Feb 17;313(7):677-86. doi: 10.1001/jama.2015.88.
10
Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.辅助泼尼松治疗社区获得性肺炎患者的多中心、双盲、随机、安慰剂对照试验。
Lancet. 2015 Apr 18;385(9977):1511-8. doi: 10.1016/S0140-6736(14)62447-8. Epub 2015 Jan 19.
Zotero 插件